ATE431143T1 - Muscarin-rezeptor-agonisten - Google Patents

Muscarin-rezeptor-agonisten

Info

Publication number
ATE431143T1
ATE431143T1 AT01995477T AT01995477T ATE431143T1 AT E431143 T1 ATE431143 T1 AT E431143T1 AT 01995477 T AT01995477 T AT 01995477T AT 01995477 T AT01995477 T AT 01995477T AT E431143 T1 ATE431143 T1 AT E431143T1
Authority
AT
Austria
Prior art keywords
receptor agonists
independently selected
muscarine receptor
orand
coch3
Prior art date
Application number
AT01995477T
Other languages
English (en)
Inventor
William Messer
Yang Cao
Original Assignee
Univ Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toledo filed Critical Univ Toledo
Application granted granted Critical
Publication of ATE431143T1 publication Critical patent/ATE431143T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01995477T 2001-01-29 2001-12-10 Muscarin-rezeptor-agonisten ATE431143T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/772,143 US6376675B2 (en) 1999-01-22 2001-01-29 Muscarinic receptor agonists
PCT/US2001/047474 WO2002060444A1 (en) 2001-01-29 2001-12-10 Muscarinic receptor agonists

Publications (1)

Publication Number Publication Date
ATE431143T1 true ATE431143T1 (de) 2009-05-15

Family

ID=25094053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01995477T ATE431143T1 (de) 2001-01-29 2001-12-10 Muscarin-rezeptor-agonisten

Country Status (9)

Country Link
US (2) US6376675B2 (de)
EP (1) EP1355646B1 (de)
JP (2) JP2004520382A (de)
AT (1) ATE431143T1 (de)
CA (1) CA2434839A1 (de)
DE (1) DE60138732D1 (de)
DK (1) DK1355646T3 (de)
ES (1) ES2327104T3 (de)
WO (1) WO2002060444A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2560756A1 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
DE602005025020D1 (de) 2004-12-27 2011-01-05 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch el
WO2007075297A2 (en) * 2005-12-27 2007-07-05 University Of Toledo Muscarinic agonists and methods of use thereof
WO2008118326A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Muscarinic agonists and methods of use thereof
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US20110294835A1 (en) 2008-05-15 2011-12-01 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
WO2009152392A2 (en) * 2008-06-11 2009-12-17 University Of Toledo Muscarinic agonists for neurological disorders and methods of making the same
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
WO2025030095A1 (en) * 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis
WO2025174424A1 (en) * 2024-02-16 2025-08-21 Terran Biosciences Inc. Analogs of xanomeline, analogs of trospium, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
WO1993014089A1 (en) 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US6096767A (en) 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists

Also Published As

Publication number Publication date
JP2010159274A (ja) 2010-07-22
CA2434839A1 (en) 2002-08-08
EP1355646A1 (de) 2003-10-29
DK1355646T3 (da) 2009-08-17
EP1355646A4 (de) 2004-06-16
ES2327104T3 (es) 2009-10-26
US6602891B2 (en) 2003-08-05
US20010036953A1 (en) 2001-11-01
US20030032658A1 (en) 2003-02-13
DE60138732D1 (de) 2009-06-25
WO2002060444A1 (en) 2002-08-08
JP2004520382A (ja) 2004-07-08
EP1355646B1 (de) 2009-05-13
US6376675B2 (en) 2002-04-23

Similar Documents

Publication Publication Date Title
ATE431143T1 (de) Muscarin-rezeptor-agonisten
EA200400794A1 (ru) Фармацевтическая композиция антагониста рецептора тахикинина в форме наночастиц
EP1423111A4 (de) Fxr-nr1h4-nuklearrezeptorbindende verbindungen
CA2536870A1 (en) Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
BR0017025A (pt) Antagonistas do receptor y5 do neuropeptìdeo y de imidazola substituìda
PL370841A1 (en) Pyrrolidine and piperidine derivates as nk1 antagonists
MY119118A (en) Thiophenopyrimidines
BR0007987A (pt) Composto, composição farmacêutica, e, processopara preparação de um composto
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
BG104437A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
GEP20084519B (en) 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
DE60016786D1 (de) Bicyclische vasopressin-agoniste
BR0006371A (pt) Compostos de 1,4-dihidropiridina substituìdos com heteroarilas de 5 membros como antagonistas de bradicinina
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
ATE121732T1 (de) Maleimidverbindungen und diese enthaltende fungizide.
EP1253139A3 (de) Multioligoanilinierte Fullerene
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
GR3035379T3 (en) Tetrazolyl-substituted quinuclidines as substance P antagonists
SE9901884D0 (sv) Novel compounds their use and preparation
ES2150739T3 (es) Compuestos triciclicos de piperidinilamino como antagonistas de sustancia p.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties